RT Journal Article
SR Electronic
T1 Routine saliva testing for the identification of silent COVID-19 infections in healthcare workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.27.20240044
DO 10.1101/2020.11.27.20240044
A1 Zhang, Kevin
A1 Shoukat, Affan
A1 Crystal, William
A1 Langley, Joanne M.
A1 Galvani, Alison P.
A1 Moghadas, Seyed M.
YR 2020
UL http://medrxiv.org/content/early/2020/11/30/2020.11.27.20240044.abstract
AB Objective Current COVID-19 guidelines recommend symptom-based screening and regular nasopharyngeal (NP) testing for healthcare personnel in high-risk settings. We sought to estimate case detection percentages with various routine NP and saliva testing frequencies.Design Simulation modelling study.Methods We constructed a sensitivity function based on the average infectiousness profile of symptomatic COVID-19 cases to determine the probability of being identified at the time of testing. This function was fitted to reported data on the percent positivity of symptomatic COVID-19 patients using NP testing. We then simulated a routine testing program with different NP and saliva testing frequencies to determine case detection percentages during the infectious period, as well as the pre-symptomatic stage.Results Routine bi-weekly NP testing, once every two weeks, identified an average of 90.7% (SD: 0.18) of cases during the infectious period and 19.7% (SD: 0.98) during the pre-symptomatic stage. With a weekly NP testing frequency, the corresponding case detection percentages were 95.9% (SD: 0.18) and 32.9% (SD: 1.23), respectively. A 5-day saliva testing schedule had a similar case detection percentage as weekly NP testing during the infectious period, but identified about 10% more cases (mean: 42.5%; SD: 1.10) during the pre-symptomatic stage.Conclusion Our findings highlight the utility of routine non-invasive saliva testing for frontline healthcare workers to protect vulnerable patient populations. A 5-day saliva testing schedule should be considered to help identify silent infections and prevent outbreaks in nursing homes and healthcare facilities.Competing Interest StatementJoanne Langley reports that Dalhousie University has received payment for conduct of vaccine studies from Sanofi, Glaxo-SmithKline, Merck, Janssen, VBI and Pfizer. Dr. Langley holds the Canadian Institutes of Health Research-GlaxoSmithKline Chair in Pediatric Vaccinology. No other competing interests were declared.Funding StatementSeyed Moghadas: CIHR (OV4-170643), COVID-19 Rapid Research; Natural Sciences and Engineering Research Council of Canada; and Canadian Foundation for Innovation. Alison Galvani: NSF (RAPID-2027755), NIH (1RO1AI151176-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was based on publicly available data and therefore did not require ethics approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe computational model with parameter values and data pertaining to the simulation study are freely available at: https://github.com/affans/npt-saliva-testing. https://github.com/affans/npt-saliva-testing